Amgen Inc.'s Stock Analysis

Amgen Annual Meeting Voting Results and Executive Compensation Approval

Amgen held its Annual Meeting on May 19, 2026, where stockholders voted on several matters. All 12 nominees for director were elected for a one-year term, and the advisory vote to approve executive compensation was passed. Additionally, Ernst & Young LLP was ratified as the company's independent registered public accountants for the fiscal year ending December 31, 2026.

A stockholder proposal to require an independent board chairman was not approved. No broker non-votes were recorded for the proposals, indicating that all votes were accounted for in the decisions made during the meeting.

May 20, 2026 16:59:48

Amgen Announces CFO Retirement and Successor Appointment

Peter H. Griffith, Chief Financial Officer of Amgen, will retire on August 31, 2026, after serving in the role since 2020. He will remain with the company in a non-executive position until January 31, 2027, during which he will receive retirement benefits as per company policies. Thomas Dittrich has been appointed as the new Chief Financial Officer, effective September 1, 2026, following a brief period as Executive Vice President starting July 1, 2026. Dittrich will relocate from Switzerland to Thousand Oaks, California, for this role.

Thomas Dittrich brings over 30 years of experience in finance and leadership, having previously served as CFO for companies such as Galderma Group AG and Shire Pharmaceuticals. His compensation package includes an annual salary of CHF 1,070,000, participation in the Global Management Incentive Plan, and significant long-term equity awards. Additionally, he will receive a one-time RSU award and a cash bonus to compensate for foregone compensation from his previous employer, along with a retention bonus and relocation benefits. This leadership transition may impact Amgen's financial strategies and operations moving forward.

May 19, 2026 16:08:12

Amgen Reports First Quarter 2026 Financial Results and Guidance

Amgen announced its financial results for the first quarter of 2026, reporting total revenues of $8.6 billion, a 6% increase compared to the same period in 2025. Product sales rose 4%, supported by a 9% volume growth, although partially offset by a decrease in net selling prices. Sixteen products achieved double-digit sales growth, and seventeen products are projected to annualize over $1 billion in sales based on first-quarter performance. GAAP earnings per share increased 4% to $3.34, while non-GAAP earnings per share rose 5% to $5.15. Free cash flow was reported at $1.5 billion, up from $1.0 billion year-over-year.

The company provided guidance for the full year 2026, estimating total revenues between $37.1 billion and $38.5 billion. GAAP earnings per share are expected to range from $15.62 to $17.10, while non-GAAP earnings per share are projected between $21.70 and $23.10. Additionally, Amgen plans capital expenditures of approximately $2.6 billion and share repurchases not exceeding $3.0 billion. The company continues to advance its pipeline, including several Phase 3 studies for the new product MariTide, which targets chronic weight management and cardiovascular outcomes.

Apr 30, 2026 16:03:26

Amgen Announces Retirement of Chief Technology Officer David Reese

Amgen Inc. has announced the retirement of David M. Reese, the Executive Vice President and Chief Technology Officer, effective June 30, 2026. Reese has been with the company since 2005 and has played a significant role in advancing the company’s research and development, leading to the approval of various innovative medicines. Following his departure, responsibilities will be redistributed among several executives to enhance the integration of science and technology within the organization.

Effective June 1, 2026, James E. Bradner will take on the role of Executive Vice President, Research and Development, Artificial Intelligence and Data, while Murdo Gordon will oversee Amgen Global Markets and Policy. Additionally, Peter H. Griffith will continue as Chief Financial Officer. These organizational changes aim to strengthen Amgen's capacity for convergent innovation, which combines biology, data science, and advanced technologies to improve patient care and streamline operations.

Apr 22, 2026 16:03:08

Amgen Issues $4.0 Billion in Senior Notes with Various Maturities

Amgen Inc. has issued a total of $4.0 billion in senior notes, which include $1 billion in 4.200% notes due 2031, $1.75 billion in 4.850% notes due 2036, $500 million in 5.500% notes due 2046, and $750 million in 5.650% notes due 2056. The company registered these notes under an effective Registration Statement and expects to receive net proceeds of approximately $3.96 billion after expenses.

The interest on these notes will be payable semi-annually starting August 19, 2026, with maturity dates ranging from 2031 to 2056. In the event of a change in control, noteholders can require Amgen to purchase their notes at a price of 101% of the principal amount plus any accrued interest. The notes will rank equally with other senior unsecured debts and will be subordinated to the company's secured obligations and its subsidiaries' obligations.

Feb 19, 2026 16:27:56

Amgen Reports 2025 Financial Results with Revenue Growth and EPS Increase

Amgen announced its financial results for the fourth quarter and full year of 2025, reporting total revenues of $9.9 billion for Q4, a 9% increase compared to the same period in 2024, and $36.8 billion for the full year, reflecting a 10% growth. Product sales also saw a 10% increase, driven by a 13% growth in volume. The company achieved record sales for 18 products and reported that 14 products exceeded $1 billion in annual sales. GAAP earnings per share (EPS) rose significantly, with an increase of 111% for Q4 and 88% for the full year, attributed to higher revenues and net unrealized gains on equity investments, despite some higher operating expenses, including a notable impairment charge related to Otezla® due to Medicare pricing changes under the Inflation Reduction Act.

For the full year, Amgen generated $8.1 billion in free cash flow, a decrease from $10.4 billion in 2024, influenced by working capital timing and increased capital expenditures. Non-GAAP EPS saw a 10% increase for the year, while operating income also improved. The company's operating expenses increased, with research and development costs notably rising by 24% in Q4, reflecting higher investment in late-stage clinical programs. Amgen's diverse portfolio continues to show growth potential, although certain products are facing competitive pressures, particularly in the inflammation and oncology segments.

Feb 03, 2026 16:03:07

Amgen Terminates Collaboration Agreement with Kyowa Kirin

Amgen Inc. has entered into a Termination Agreement with Kyowa Kirin Co., Ltd. to end their License and Collaboration Agreement that was established on June 1, 2021. The termination will take effect once regulatory approval is obtained.

This decision reflects a significant change in Amgen's strategic partnerships, which may impact its future business operations and collaborations. The details of the Termination Agreement are documented in Exhibit 10.1, which is referenced in the filing.

Jan 30, 2026 08:00:41

Amgen Reports Third Quarter 2025 Financial Results and Guidance

Amgen announced its financial results for the third quarter of 2025, reporting total revenues of $9.6 billion, a 12% increase from the same period in 2024. Product sales also grew by 12%, bolstered by a 14% increase in volume, although offset by a 4% decrease in net selling prices. The company's GAAP earnings per share rose 14% to $5.93, while non-GAAP earnings per share increased 1% to $5.64. Free cash flow for the quarter was reported at $4.2 billion, up from $3.3 billion year-over-year, reflecting favorable working capital timing and lower interest payments despite higher capital expenditures.

Amgen provided guidance for the full year 2025, projecting total revenues between $35.8 billion and $36.6 billion. The company anticipates GAAP earnings per share in the range of $13.76 to $14.60 and non-GAAP earnings per share between $20.60 and $21.40. Additionally, Amgen plans capital expenditures of $2.2 billion to $2.3 billion and share repurchases not to exceed $500 million. The company also noted ongoing Phase 3 studies for its product MariTide, which focuses on chronic weight management and cardiovascular outcomes.

Nov 04, 2025 16:04:18

Amgen Reports Second Quarter 2025 Financial Performance Details

Amgen announced its financial results for the second quarter of 2025, reporting total revenues of $9.2 billion, a 9% increase from the same period in 2024. Product sales also grew by 9%, with notable increases in sales for several key products, including Repatha and EVENITY, which saw double-digit growth. GAAP earnings per share rose significantly by 92% to $2.65, while non-GAAP earnings per share increased 21% to $6.02. The company generated $1.9 billion in free cash flow during the quarter, a decrease from $2.2 billion in the previous year due to deferred tax payments and higher capital expenditures.

In terms of operating expenses, Amgen reported an increase of 1% year-over-year for total operating expenses on a GAAP basis, while non-GAAP operating expenses rose by 8%. The company’s operating margin improved on both GAAP and non-GAAP bases, reaching 30.3% and 48.9%, respectively. As of June 30, 2025, Amgen had cash and cash equivalents of $8.0 billion and outstanding debt of $56.2 billion. The company has also outlined its guidance for the full year, expecting total revenues between $35.0 billion and $36.0 billion, along with projected earnings per share ranges for both GAAP and non-GAAP measures.

Aug 05, 2025 16:03:34

Amgen Reports 9% Revenue Growth and Positive Earnings in Q1 2025

Amgen announced its financial results for the first quarter of 2025, reporting total revenues of $8.1 billion, a 9% increase from the same period in 2024. Product sales rose by 11%, with U.S. sales growing 14%. Notable contributors to sales growth included Repatha, BLINCYTO, and TEZSPIRE, among others. The company also launched IMDELLTRA, which generated $81 million in sales during the quarter. GAAP earnings per share were $3.20, a significant recovery from a loss of $0.21 in the previous year, driven by an unrealized gain on an equity investment, despite an $800 million impairment charge related to Otezla. Non-GAAP EPS increased 24% to $4.90, reflecting higher revenues and increased operating expenses. The company generated $1.0 billion in free cash flow, up from $0.5 billion a year earlier, and declared a quarterly dividend of $2.38, a 6% increase from 2024.

Operating expenses rose 8% year-over-year, while the operating margin improved to 15.0%. The tax rate increased significantly due to changes in earnings mix. Amgen reduced its outstanding debt by $2.8 billion during the quarter and reported cash and cash equivalents of $8.8 billion. For the full year 2025, the company projects total revenues between $34.3 billion and $35.7 billion, with GAAP EPS guidance of $12.21 to $13.46 and non-GAAP EPS of $20.00 to $21.20. The company continues to progress on various product developments and pipeline studies, including multiple Phase 3 trials across its therapeutic areas.

May 01, 2025 16:04:20